<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00700947</url>
  </required_header>
  <id_info>
    <org_study_id>2007H0120</org_study_id>
    <secondary_id>AHA-0335098N</secondary_id>
    <nct_id>NCT00700947</nct_id>
  </id_info>
  <brief_title>Using Beta Blockers to Treat Mitral Regurgitation</brief_title>
  <acronym>REGURG</acronym>
  <official_title>Beta-Blockade in Chronic Mitral Regurgitation: Moving From the Laboratory Experiment to Clinical Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study tests whether beta-blocker will benefit asymptomatic patients with
      chronic primary mitral regurgitation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study tests 1) whether Toprol xl, a beta-blocker will benefit
      asymptomatic patients with chronic primary mitral regurgitation; 2) investigate the effects
      of chronic mitral regurgitation on left ventricular remodeling, left ventricular
      function,exercise capacity and clinical symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding terminated
  </why_stopped>
  <start_date type="Actual">October 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change on Neurohormonal Measurements</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Change is calculated as the value at 6 months minus the value at baseline. The following neurohormones are measured: Brain type Natriuretic Peptide (BNP), tumor necrosis factor- alpha ( TNF- alpha), norepinephrine, epinephrine and plasma renin activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Left Ventricular Ejection Fraction</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Measured on Echocardiogram. Change is calculated as the value at 6 months minus the value at baseline. Assess the systolic function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on Left Ventricle end- Diastolic (LVEDD) and end-Systolic dimensions</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Measured on Echocardiogram. Change is calculated as the value at 6 months minus the value at baseline. Assess Left ventricular remodeling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on Left Ventricle end- Diastolic (LVEDD) and end-Systolic Volumes</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Measured on Echocardiogram. Change is calculated as the value at 6 months minus the value at baseline. Assess Left ventricular remodeling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change on Left Ventricular Mass</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Measured on Echocardiogram. Change is calculated as the value at 6 months minus the value at baseline. Assess Left ventricular remodeling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on the Regurgitant Stroke Volume</measure>
    <time_frame>6 months</time_frame>
    <description>Measured on Echocardiogram. This will be calculated using the proximal isovelocity surface area (PISA) method.Change is calculated as the value at 6 months minus the value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary Venous Systolic Flow Reversal</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Measured on Echocardiogram Color Doppler mapping of Mitral Regurgitation (MR) jets will be used to semiquantitative asses severity of MR using a 4 point scale( 1-4, where higher scores denotes worse outcomes).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Heart Disease</condition>
  <condition>Mitral Regurgitation</condition>
  <condition>Heart Valve Disease</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are asymptomatic with normal left ventricular systolic function and who agree to be treated medically for severe primary mitral regurgitation with Beta-blocker therapy. Patients may entered into the Arm 2 (surgical treatment) later on when they develop symptoms or enlarged left ventricle or left ventricular dysfunction or wishes to have surgical treatment of severe primary mitral regurgitation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be surgically treated for severe primary mitral regurgitation as a routine clinical care if they want to be treated surgically or develop symptoms or significant adverse left ventricular remodeling or left ventricular dysfunction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Health Control includes the subjects with no remarkable past medical history and not currently taking any medications. Normal subjects will be used for comparison with patients with severe primary mitral regurgitation in term of clinical, echocardiographic and neuro-hormonal findings.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta-blocker therapy (TOPROL-XL® )</intervention_name>
    <description>Patients who are asymptomatic with normal left ventricular systolic function and wish to be medically treated for severe primary mitral regurgitation with Beta-blocker.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of sever primary mitral regurgitation

          -  Normal subjects

        Exclusion Criteria:

          -  Left ventricle ejection fraction of &lt;55% pre and post operation

          -  Pregnancy or Lactation

          -  Secondary mitral regurgitation due to coronary artery disease, cardiomyopathy,
             uncontrolled hypertension, or severe aortic stenosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Pu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Wake Forest University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Yang H, Davidson WR Jr, Chambers CE, Pae WE, Sun B, Campbell DB, Pu M. Preoperative pulmonary hypertension is associated with postoperative left ventricular dysfunction in chronic organic mitral regurgitation: an echocardiographic and hemodynamic study. J Am Soc Echocardiogr. 2006 Aug;19(8):1051-5.</citation>
    <PMID>16880102</PMID>
  </reference>
  <reference>
    <citation>Pu M, Gao Z, Li J, Sinoway L, Davidson WR Jr. Development of a new animal model of chronic mitral regurgitation in rats under transesophageal echocardiographic guidance. J Am Soc Echocardiogr. 2005 May;18(5):468-74.</citation>
    <PMID>15891757</PMID>
  </reference>
  <results_reference>
    <citation>Pu M, Gao Z, Pu DK, Davidson WR Jr. Effects of early, late, and long-term nonselective β-blockade on left ventricular remodeling, function, and survival in chronic organic mitral regurgitation. Circ Heart Fail. 2013 Jul;6(4):756-62. doi: 10.1161/CIRCHEARTFAILURE.112.000196. Epub 2013 Apr 11.</citation>
    <PMID>23580745</PMID>
  </results_reference>
  <results_reference>
    <citation>Pu M, Gao Z, Zhang X, Liao D, Pu DK, Brennan T, Davidson WR Jr. Impact of mitral regurgitation on left ventricular anatomic and molecular remodeling and systolic function: implication for outcome. Am J Physiol Heart Circ Physiol. 2009 Jun;296(6):H1727-32. doi: 10.1152/ajpheart.00882.2008. Epub 2009 Mar 27.</citation>
    <PMID>19329766</PMID>
  </results_reference>
  <results_reference>
    <citation>Pu M. The frequency, impact, and management of mitral regurgitation in patients with heart failure. Curr Cardiol Rep. 2006 May;8(3):226-31. Review.</citation>
    <PMID>17543250</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Disease</keyword>
  <keyword>Mitral Regurgitation</keyword>
  <keyword>Heart Valve Disease</keyword>
  <keyword>Mitral Valve Insufficiency</keyword>
  <keyword>Heart Surgery</keyword>
  <keyword>Heart Valve Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We currently have no plan to share participant data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

